drugset / Trial / NCT02892071

Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma

NCT02892071

Phase 1 Withdrawn SUZAN OBAGI
RandomizedParallel-groupSingle-blindTreatment

Summary

Tri-split face study of skin resurfacing modalities for the treatment of melasma, comparing the medium depth trichloroacetic acid peel, CO2 laser and Qs-NdYag laser.

Timeline

Start
2020-12
Primary completion
2022-09
Completion
2022-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Trichloroacetic acid Small molecule 22 %